12 August 2016

ASX ANNOUNCEMENT

European Penthrox® Update.

Medical Developments International Limited (ASX: MVP) advises that the roll out and acceptance of Penthrox in the United Kingdom, Republic of Ireland and the EU is going to plan.

CEO of Medical Developments, Mr. John Sharman said: “We have just received our first order from Mundipharma for the French market and expect another order shortly for Belgium. The French order is the largest single order in our company’s history.”

In the United Kingdom, Penthrox was launched in February 2016 and in the Republic of Ireland in April 2016. Since that time, MVP’s marketing partner Galen Limited has worked closely with major hospitals in the preparation and submission of more than 130 Hospital Formulary Applications. The hospitals targeted in the first phase of formulary applications cover a significant percentage of the emergency cases seen in the UK and Ireland.

Galen Managing Director Mr. David Bennett said:

“Formulary applications take circa 6 months before a new product is listed for use. So far, we have achieved 11 formulary listings and we have confirmed hospital drug and therapeutic committee dates for a further 21. Our roll out of Penthrox is going to plan and we are very confident of acceptance in the Emergency Departments.

In terms of Ambulance, South East Coast Ambulance Service, one of ten Ambulance Trusts in England, is currently using Penthrox and administering doses to patients. South East Coast Ambulance Service has completed an “in market” evaluation and shared the preliminary results in the Spring Edition of Ambulance Today. By the end of the year, the South East Coast Ambulance Service evaluation is expected to be published and reviewed by the Joint Royal Colleges Ambulance Liaison Committee (JRCALC), which should result in a positive recommendation and adoption by all Ambulance Trusts.

In the Republic of Ireland, the Pre-Hospital Emergency Care Council (PHECC) guidelines are expected to be published in September with the inclusion of Penthrox, which will result in adoption across the National Ambulance Service. The response to Penthrox has been extremely positive and we have already received 9 formulary listings from major hospitals.”

Mr Sharman said: “In addition to the UK, Ireland, France and Belgium we are confident of introducing Penthrox to the other European countries during 2017 and confirming our expectations in terms of the market penetration and uptake of Penthrox. Elsewhere in Europe we are also progressing our plans with some Eastern Bloc countries.”
Enquiries:

John Sharman  
Chief Executive Officer  
Medical Developments International Ltd  
03 9547 1888

David Williams  
Chairman  
Medical Developments International Ltd  
0414 383 593
About Penthrox
Penthrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox has been used safely and effectively for more than 30 years in Australia with excess of 6.0 million units sold. There is growing interest in Penthrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

About Medical Developments International Ltd
MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox®, a fast acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

About Galen Ltd
Galen is a leading UK specialty pharmaceutical sales and marketing company, which has a significant presence in the UK and Irish markets. Galen is part of the Almac group which has in excess of 3,300 employees worldwide and is headquartered in Belfast, Ireland. Galen’s intimate knowledge of the target markets in the UK and Ireland will allow it to establish Penthrox as the leading product in self-administered trauma pain relief in the hospital and pre hospital environments.

About Mundipharma
The Mundipharma network of independent associated companies consists of privately owned companies and joint ventures covering the world's pharmaceutical markets. These companies are committed to bringing to patients the benefits of pioneering treatment options in the core therapy areas of pain management, oncology, respiratory and inflammatory conditions. Through innovation, design and acquisition, the Mundipharma network of independent associated companies delivers important treatments to meet the most pressing needs of patients, healthcare professionals and health systems worldwide.